MDXH — MDxHealth S.A.

MDxHealth S.A. Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Revenue: Q3 revenue reached $27.4 million, an 18% increase from $23.3 million in Q3 2024.
• Adjusted EBITDA: Positive at $1 million, compared to a negative $3.8 million in Q3 2024.
• Gross Profit: Increased to $17.9 million, up 25% year-over-year, with gross margins improving to 65.2% from 61.2%.
• Operating Loss: Reduced by 57% to $2.6 million from $6.1 million in the prior year.
• Net Loss: Decreased 28% to $8 million compared to $11.2 million in Q3 2024.
• Total Billable Volume: Approximately 33,000 tests, with liquid-based tests growing 65% year-over-year.

2. Strategic Updates and Business Highlights:

• Acquisition of Exosome Diagnostics: Positioned MDxHealth with a comprehensive menu of precision diagnostics in urology, enhancing their offerings for prostate cancer diagnostics.
• Sales Growth: The sales organization achieved a 45% compound annual growth rate over the past four years while maintaining flat sales and marketing expenses as a percentage of revenue.
• Laboratory Operations: Expanded to three labs, focusing on operational efficiency and quality improvements.
• Customer Experience Focus: Emphasis on improving turnaround times and overall customer satisfaction, aiming to set new industry standards.

3. Forward Guidance and Outlook:

• MDxHealth expects to maintain revenue guidance of $108 million to $110 million for 2025, despite pausing entry into the germline market.
• The integration of the ExoDx acquisition is a top priority for Q4, with expectations of contributing positively to revenue in 2026.
• The company anticipates continued top-line growth and improved operating profitability, with a focus on disciplined capital allocation.

4. Bad News, Challenges, or Points of Concern:

• Germline Market Deemphasis: The decision to pause the germline offering could impact expected revenues, as it was initially anticipated to contribute significantly to 2025 guidance.
• Sales Strategy Adjustments: Transitioning customers from Select to Exo may pose challenges, although management is optimistic about a smooth integration.
• ASP Fluctuations: Concerns were raised regarding a potential decline in average selling prices (ASP) for tissue tests, although management did not confirm any significant changes.
• Competitive Pressures: The competitive landscape in the diagnostics market remains intense, with multiple players offering similar tests.

5. Notable Q&A Insights:

• ExoDx Contribution: Management indicated that ExoDx did not contribute materially in Q3 due to the timing of the acquisition but expects it to enhance revenue moving forward.
• GPS Performance: Tissue-based tests, including GPS, showed an 18% growth, with management expressing confidence in sustaining this performance despite a slight slowdown in biopsy volumes.
• Sales Team Expansion: The addition of 10 new sales reps from ExoDx is aimed at optimizing cross-selling opportunities and enhancing customer engagement.
• Market Strategy Reevaluation: Management plans to reassess the germline market opportunity in 2026, indicating a strategic pivot based on market conditions and internal capabilities.

Overall, MDxHealth S.A. reported solid financial growth in Q3 2025, driven by strategic acquisitions and a focus on operational efficiency, while navigating challenges related to market dynamics and product transitions.